Nuvation Bio Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Nuvation Bio Inc. (NUVB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -1.17% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-03-02
- Nuvation Bio Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2025 was -1.17%.
- Nuvation Bio Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was -0.10%.
- Nuvation Bio Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.09%, a 123.08% decline from fiscal 2021.
- Nuvation Bio Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 0.39%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -1.17% 10-K · filed 2026-03-02 | |
| 2023-12-31 | -0.10% 10-K · filed 2024-02-29 | |
| 2022-12-31 | -0.09% 10-K · filed 2024-02-29 | 1.65% 10-K · filed 2023-03-15 |
| 2021-12-31 | 0.39% 10-K · filed 2023-03-15 | |
| 2020-12-31 | -1.46% 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |